Gynecological clear cell cancers (CCCs), very aggressive forms of ovarian and endometrial malignancies, respond poorly to chemotherapy.  The low respo | Cancer ...

Recent research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

Researchers from Helmholtz Munich and the Technical University of Munich have developed a novel method to track cancer treatment responses in individual cells—without the need for dyes or labels.

Landmark research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some promising cancer treatments are causing serious side effects, and offers ...

(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA ® (tislelizumab), in combination with gemcitabine and cisplatin, ...

Stem cell tech simulates ALS, quantum tools decode quasicrystals, and cancer exploits a human mutation—three breakthroughs ...

BeOne Medicines has secured approval from the European Commission (EC) for Tevimbra (tislelizumab) to be used along with ...

A genetically diverse mouse model allowed researchers to identify genes that promote the success of immune checkpoint ...

Molecular glues, tiny molecules that connect one protein to another, are promising targets for pharmaceutical research. By ...

Cell death terminates normal cellular functions, including respiration, metabolism, growth and proliferation. Cell death can be non-programmed, for example as the result of accidental injury or ...

The authors proposed two hypotheses: first, that methamphetamine induces neuroinflammation, and second, that it alters neuronal stem cell differentiation. These are valuable hypotheses, and the ...